Related references
Note: Only part of the references are listed.Low Rates of Naturally Occurring Resistant Variants to the NS5A Inhibitor Daclatasvir in HCV-1 Null Responders
Enrico Galmozzi et al.
HEPATOLOGY (2013)
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B
Katharina Esser-Nobis et al.
HEPATOLOGY (2013)
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
Thibaut Vausselin et al.
HEPATOLOGY (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New Protease Inhibitors for the Treatment of Chronic Hepatitis C A Cost-Effectiveness Analysis
Shan Liu et al.
ANNALS OF INTERNAL MEDICINE (2012)
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
Vincenzo Summa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
Angela M. Lam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase
Leen Delang et al.
ANTIVIRAL RESEARCH (2012)
Rapid and sharp decline in HCV upon monotherapy with NS3 protease inhibitor, ACH-1625
Atul Agarwal et al.
ANTIVIRAL THERAPY (2012)
Second generation direct antivirals and the way to interferon-free regimens in chronic HCV
Heather Lewis et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
The role of resistance in HCV treatment
Johannes Vermehren et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity
X. Christopher Sheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease
X. Christopher Sheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C
Mei H. Chang et al.
CLINICAL THERAPEUTICS (2012)
TMC435 for the treatment of chronic hepatitis C
Sudeep Tanwar et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Telaprevir for the treatment of hepatitis C
Nicole Forestier et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2012)
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye
Geoffrey Dusheiko et al.
GUT (2012)
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
Calogero Camma et al.
HEPATOLOGY (2012)
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052
Jin-Hua Sun et al.
HEPATOLOGY (2012)
Antiviral strategies in hepatitis C virus infection
Christoph Sarrazin et al.
JOURNAL OF HEPATOLOGY (2012)
12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333+RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS
F. Poordad et al.
JOURNAL OF HEPATOLOGY (2012)
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin
Dominique Larrey et al.
JOURNAL OF HEPATOLOGY (2012)
Hepatitis C therapy in non-genotype 1 patients: the near future
C. Wartelle-Bladou et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
F. Poordad et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
Robert J. Fontana et al.
LIVER TRANSPLANTATION (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
Christy M. Hebner et al.
PLOS ONE (2012)
Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein
Oscar Belda et al.
VIRUS RESEARCH (2012)
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
Keith P. Romano et al.
PLOS PATHOGENS (2012)
New opportunities in anti-hepatitis C virus drug discovery: Targeting NS4B
Roopa Rai et al.
ANTIVIRAL RESEARCH (2011)
Mixing and Matching Drugs: What Makes Sense?
Tania M. Welzel et al.
CLINICS IN LIVER DISEASE (2011)
Second-wave Protease Inhibitors: Choosing an Heir
Sandra Ciesek et al.
CLINICS IN LIVER DISEASE (2011)
The NS5A Replication Complex Inhibitors: Difference Makers?
Robert G. Gish et al.
CLINICS IN LIVER DISEASE (2011)
Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell et al.
HEPATOLOGY (2011)
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
Nigel J. Liverton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease
Peter W. White et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin et al.
GASTROENTEROLOGY (2010)
Identification of Hepatitis C Virus NS5A Inhibitors
Julie A. Lemm et al.
JOURNAL OF VIROLOGY (2010)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao et al.
NATURE (2010)
New Insights into Structure and Replication of the Hepatitis C Virus and Clinical Implications
Marion Poenisch et al.
SEMINARS IN LIVER DISEASE (2010)
In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
Tse-I Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture
Immacolata Conte et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
HCV796: A Selective Nonstructural Protein 5B Polymerase Inhibitor with Potent Anti-Hepatitis C Virus Activity In Vitro, in Mice with Chimeric Human Livers, and in Humans Infected with Hepatitis C Virus
Norman M. Kneteman et al.
HEPATOLOGY (2009)
Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
Scott D. Seiwert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796
Anita Y. M. Howe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Treatment predictors of a sustained virologic response in hepatitis B and C
Annika Kau et al.
JOURNAL OF HEPATOLOGY (2008)
Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis
Shirit Einav et al.
NATURE BIOTECHNOLOGY (2008)
Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus
Eike Steinmann et al.
HEPATOLOGY (2007)
Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate
Martin J. Slater et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
GSK625433; A novel and highly potent inhibitor of the HCVNS5B polymerase
F. Gray et al.
JOURNAL OF HEPATOLOGY (2007)
Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus
Sophie Le Pogam et al.
JOURNAL OF VIROLOGY (2006)
Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site
S Di Marco et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase
TL Tellinghuisen et al.
NATURE (2005)
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay
SW Ludmerer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase
L Tomei et al.
JOURNAL OF VIROLOGY (2003)
Share Paper
